Combined Ketamine and eCBT Intervention for PTSD
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Post Traumatic Stress Disorder
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Participants diagnosed with PTSD will be randomly assigned either to the experimental treatment or a waitlist control. Data will be collected from participants in both groups at the same 3 time-points.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 65 years
- Gender
- Both males and females
Description
OBJECTIVES (i) To introduce a previously untreated patient population with PTSD to new therapeutic options. (ii) To provide new insights into the functional role of Glutamate in affective disorders as well as in learning and memory. (iii) To explore the utility of pharmacologically-enhanced psychoth...
OBJECTIVES (i) To introduce a previously untreated patient population with PTSD to new therapeutic options. (ii) To provide new insights into the functional role of Glutamate in affective disorders as well as in learning and memory. (iii) To explore the utility of pharmacologically-enhanced psychotherapy. OUTLINE The present study is an open label randomized control trial assessing the efficacy of a combined treatment of sub-anaesthetic IV Ketamine in conjunction with online CBT (eCBT). In the study, 20 participants with refractory PTSD will be randomly assigned either to an experimental group receiving a combination of Ketamine and eCBT over 14 weeks, or they will be assigned to a 14-week waitlist-control group (at the end of which they would receive the experimental treatment). Both groups will be assessed for symptoms of PTSD and comorbid disorders before treatment, at the 7-week halfway point, and at the end of the 14 week experimental period. Symptoms of PTSD and comorbid disorders for participants in the experimental group are expected to improve significantly more than participants in the waitlist-control.
Tracking Information
- NCT #
- NCT04771767
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Taras Reshetukha, MD Queen's University
Get Well Soon